Citations

Clear

3030 citation(s) found for "Susan, M".

Update on Gender Equity in Immunology, 2001 to 2016
Kovats, Susan , Parent, Michelle A., Gaffen, Sarah L. , Hedrick, Catherine C. , Denzin, Lisa , Raghavan, Malini , Stephens, Robin , Shapiro, Virginia Smith , Kovats, Susan , Raghavan, Malini , Jain, Pooja

Mayo Clinic

The Journal of Immunology | October 18, 2016 | Volume: 197 | Issue: 10 | Pages: 3751-3753

10.4049/jimmunol.1601644 | PMID 27798172 Get It

Abstract In 2001, The American Association of Immunologists Committee on the Status of Women conducted a survey examining the percentage of women faculty members within immunology departments or women in immunology graduate programs across 27 institutions in the United States, comparing it to the percentage of women receiving a Ph.D. Here, we examine the representation of women across these same 27 immunology departments and programs to examine changes in gender equity over the last 15 years.
Learning about the experience of living with chronic conditions: A framework analysis of nursing students’ reflections on their conversations with older adults
Reiland, Stephanie, Davies, Susan, Koehler, Amy Reitmaier, Olson, Amanda, Davies, Susan

Mayo Clinic

Gerontology & Geriatrics Education | October 17, 2016 | Volume: 39 | Issue: 3 | Pages: 295-315

10.1080/02701960.2016.1247067 | PMID 27749153 Get It

P4‐108: Leptin, Adiponectin and Cognition in Middle‐Aged Hiv‐Infected and Uninfected Women: The Brooklyn Women’s Interagency HIV Study
Gustafson, Deborah , Holman, Susan, Crystal, Howard, Mielke, Michelle M. , Keating, Sheila M. , MINKOFF, HOWARD L.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_22 | Pages: No page available

10.1016/j.jalz.2016.06.2199 Get It

Considering sex as a biological variable in preclinical research
Miller, Leah, Marks, Cheryl L., Hurn, Patricia D., Woodruff, Teresa K. , Sohrabji, Farida , Schiebinger, Londa , Wetherington, Cora Lee, Makris, Susan L. , Arnold, Arthur P. , Einstein, Gillian , Miller, Virginia M. , Sandberg, Kathryn , Maier, Susan, Cornelison, Terri L., Becker, Jill B. , Chen, Wei‐Jung , McCarthy, Margaret M. , Clayton, Janine A. , Schiebinger, Londa

Mayo Clinic

The FASEB Journal | September 28, 2016 | Volume: 31 | Issue: 1 | Pages: 29-34

10.1096/fj.201600781r | PMID 27682203 Get It

In June 2015, the National Institutes of Health (NIH) released a Guide notice (NOT‐OD‐15–102) that highlighted the expectation of the NIH that the possible role of sex as a biologic variable be factored into research design, analyses, and reporting of vertebrate animal and human studies. Anticipating these guidelines, the NIH Office of Research on Women's Health, in October 2014, convened key stakeholders to discuss methods and techniques for integrating sex as a biologic variable in preclinical research. The workshop focused on practical methods, experimental design, and approaches to statistical analyses in the use of both male and female animals, cells, and tissues in preclinical research. Workshop participants also considered gender as a modifier of biology. This article builds on the workshop and is meant as a guide to preclinical investigators as they consider methods and techniques for inclusion of both sexes in preclinical research and is not intended to prescribe exhaustive/specific approaches for compliance with the new NIH policy.—Miller, L. R., Marks, C., Becker, J.B., Hurn, P.D., Chen, W.‐J., Woodruff, T., McCarthy, M.M., Sohrabji, F., Schiebinger, L., Wetherington, C.L., Makris, S., Arnold, A. P., Einstein, G., Miller, V. M., Sandberg, K., Maier, S., Cornelison, T. L., Clayton, J. A. Considering sex as a biological variable in preclinical research. FASEB J. 31, 29–34 (2017) www.fasebj.org
No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival
Sucheston‐Campbell, Lara, Cannioto, Rikki , Clay‐Gilmour, Alyssa , Etter, John Lewis , Eng, Kevin H., Liu, Song , Battaglia, Sebastiano , Szender, J. Brian, Minlikeeva, Albina N. , Joseph, Janine M. , Mayor, Paul , Abrams, Scott I. , Wallace, Paul K. , Soh, Kah Teong , Zsíros, Emese , Beckmann, Matthias W. , Bruegl, Amanda , Campbell, Ian , Campbell, Shawn, Chenevix‐Trench, Georgia , Diergaarde, Brenda , Doerk, Thilo, Eccles, Diana , Engelholm, Svend Aage, Fasching, Peter A. , Gayther, Simon A. , Goodman, Marc T. , Harter, Philipp , Hein, Alexander , Heitz, Florian , Hillemmanns, Peter, Høgdall, Claus , Høgdall, Estrid , Huzarski, Tomasz , Jensen, Allan , Johnatty, Sharon E. , Jung, Audrey , Klapdor, Reudiger, Kluz, Tomasz , Konopka, Bożena , Kupryjańczyk, Jolanta , Lambrechts, Diether , Lester, Jenny, Lubiński, Jan , Levine, Douglas A. , Lundvall, Lene, McGuire, Valerie , McNeish, Iain A. , Menon, Usha , Ness, Roberta B., Oršulić, Sandra , Pearce, Celeste Leigh, Ramus, Susan J. , Rothstein, Joseph H. , Rossing, Mary Anne, Rübner, Matthias, Schildkraut, Joellen M. , Schmalfeldt, Barbara , Schwaab, Ira, Sieh, Weiva , Sobiczewski, Piotr , Song, Honglin , Terry, Kathryn L. , Nieuwenhuysen, Els Van , Vanderstichele, Adriaan , Vergote, Ignace , Walsh, Christine , Webb, Penelope M. , Wentzensen, Nicolas , Whittemore, Alice S. , Wu, Anna H. , Odunsi, Kunle , Chang‐Claude, Jenny , Goode, Ellen L. , Moysich, Kirsten B. , Dörk, Thilo , Bowtell, David D.L. , Lambrechts, Diether , Clay, Alyssa I, Hu, Qiang , Segal, Brahm H. , Anton‐Culver, Hoda , Bandera, Elisa V. , Berchuck, Andrew , Bjørge, Line , Cramer, Daniel W. , Dansonka‐Mieszkowska, Agnieszka , Dao, Fanny , Doherty, Jennifer A. , Bois, Andreas du , Gentry‐Maharaj, Aleksandra , Glasspool, Rosalind , Gronwald, Jacek , Karlan, Beth Y. , Kjær, Susanne K. , Modugno, Francesmary , Paul, James , Pejovic, Tanja B. , Pharoah, Paul D.P. , Siddiqui, Nadeem , Ziogas, Argyrios , Dörk, Thilo , Lambrechts, Diether , McNeish, Iain A , Ramus, Susan J , Vanderstichele, Adriaan , Webb, Penelope M , Hein, Alexander , Jensen, Allan , Eccles, Diana , Menon, Usha , Moysich, Kirsten , Campbell, Ian G , Heitz, Florian , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Huzarski, Tomasz , Jung, Audrey Y , Bowtell, David D , Diergaarde, Brenda , Lubinski, Jan , Kluz, Tomasz , Goodman, Marc T

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 28, 2016 | Volume: 26 | Issue: 3 | Pages: 420-424

10.1158/1055-9965.epi-16-0631 | PMID 27677730 Get It

Abstract Background: The precise mechanism by which the immune system is adversely affected in cancer patients remains poorly understood, but the accumulation of immunosuppressive/protumorigenic myeloid-derived suppressor cells (MDSCs) is thought to be a prominent mechanism contributing to immunologic tolerance of malignant cells in epithelial ovarian cancer (EOC). To this end, we hypothesized genetic variation in MDSC pathway genes would be associated with survival after EOC diagnoses. Methods: We measured the hazard of death due to EOC within 10 years of diagnosis, overall and by invasive subtype, attributable to SNPs in 24 genes relevant in the MDSC pathway in 10,751 women diagnosed with invasive EOC. Versatile Gene-based Association Study and the admixture likelihood method were used to test gene and pathway associations with survival. Results: We did not identify individual SNPs that were significantly associated with survival after correction for multiple testing (P < 3.5 × 10−5), nor did we identify significant associations between the MDSC pathway overall, or the 24 individual genes and EOC survival. Conclusions: In this well-powered analysis, we observed no evidence that inherited variations in MDSC-associated SNPs, individual genes, or the collective genetic pathway contributed to EOC survival outcomes. Impact: Common inherited variation in genes relevant to MDSCs was not associated with survival in women diagnosed with invasive EOC. Cancer Epidemiol Biomarkers Prev; 26(3); 420–4. ©2016 AACR.
A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer
Vijai, Joseph , Topka, Sabine , Villano, Danylo , Ravichandran, Vignesh , Maria, Ann, Gaddam, Pragna, Lincoln, Anne , Kazzaz, Sarah A. , Wenz, Brandon M., Carmi, Shai , Schrader, Kasmintan A. , Hart, Steven N. , Lipkin, Steve M., Walsh, Michael F. , Zhang, Liying , Lejbkowicz, Flavio, Rennert, Hedy S., Weitzel, Jeffrey N. , Daly, Mark J., Nathanson, Katherine L. , Rennert, Gad , Offit, Kenneth , Maxwell, Kara N. , Thomas, Tinu , Neuhausen, Susan L. , Stadler, Zsofia , Robson, Mark E. , Domchek, Susan M. , Couch, Fergus J. , Norton, Larry , Schrader, Intan , Rennert, Gad , Weitzel, Jeffrey N , Joseph, Vijai , Hart, Steven N , Nathanson, Katherine L , Ravichandran, Vignesh , Topka, Sabine

Mayo Clinic

Cancer Discovery | September 21, 2016 | Volume: 6 | Issue: 11 | Pages: 1267-1275

10.1158/2159-8290.cd-16-0487 | PMID 27655433 Get It

Abstract Known gene mutations account for approximately 50% of the hereditary risk for breast cancer. Moderate and low penetrance variants, discovered by genomic approaches, account for an as-yet-unknown proportion of the remaining heritability. A truncating mutation c.325C>T:p.Arg109* (R109X) in the ATP-dependent helicase ERCC3 was observed recurrently among exomes sequenced in BRCA wild-type, breast cancer–affected individuals of Ashkenazi Jewish ancestry. Modeling of the mutation in ERCC3-deficient or CRISPR/Cas9-edited cell lines showed a consistent pattern of reduced expression of the protein and concomitant hypomorphic functionality when challenged with UVC exposure or treatment with the DNA alkylating agent IlludinS. Overexpressing the mutant protein in ERCC3-deficient cells only partially rescued their DNA repair–deficient phenotype. Comparison of frequency of this recurrent mutation in over 6,500 chromosomes of breast cancer cases and 6,800 Ashkenazi controls showed significant association with breast cancer risk (ORBC = 1.53, ORER+ = 1.73), particularly for the estrogen receptor–positive subset (P < 0.007). Significance: A functionally significant recurrent ERCC3 mutation increased the risk for breast cancer in a genetic isolate. Mutated cell lines showed lower survival after in vitro exposure to DNA-damaging agents. Thus, similar to tumors arising in the background of homologous repair defects, mutations in nucleotide excision repair genes such as ERCC3 could constitute potential therapeutic targets in a subset of hereditary breast cancers. Cancer Discov; 6(11); 1267–75. ©2016 AACR. This article is highlighted in the In This Issue feature, p. 1197
Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development
Forman, Mark S., DeSanti, Susan, Kozauer, Nicholas, Petersen, Ronald C. , Randolph, Christopher , Isaac, Maria , Mattsson, Niklas , Bain, Lisa J. , Hendrix, James A. , Sims, John R. , Rabinovici, Gil D. , Carrillo, María C. , Miller, David S., Knopman, David S. , Smith, Eric Edward

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | September 20, 2016 | Volume: 3 | Issue: 1 | Pages: 83-91

10.1016/j.trci.2016.09.002 | PMID 29067320 Get It

Abstract Dementia is often characterized as being caused by one of several major diseases, such as Alzheimer's disease (AD), cerebrovascular disease, Lewy body disease, or a frontotemporal degeneration. Failure to acknowledge that more than one entity may be present precludes attempts to understand interactive relationships. The clinicopathological studies of dementia demonstrate that multiple pathologic processes often coexist. How overlapping pathologic findings affect the diagnosis and treatment of clinical AD and other dementia phenotypes was the topic taken up by the Alzheimer's Association's Research Roundtable in October 2014. This review will cover the neuropathologic basis of dementia, provide clinical perspectives on multiple pathologies, and discuss therapeutics and biomarkers targeting overlapping pathologies and how these issues impact clinical trials.High prevalence of multiple pathologic findings among individuals with clinical diagnosis of AD suggests that new treatment strategies may be needed to effectively treat AD and other dementing illnesses.
The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant‐Associated Infection Surveillance Network (TRANSNET)
Andes, David R. , Safdar, Nasia , Alexander, Barbara D. , Brumble, Lisa , Freifeld, Allison, Hadley, Susan , Herwaldt, Loreen A. , Kauffman, Carol A., Lyon, G. Marshall, Morrison, Vicki A., Perl, Trish M. , Walker, Randall C., Hess, Tim, Chiller, Tom , Pappas, Peter G. , Investigators, The TRANSNET, Walker, Randall, Baddley, John W. , Patterson, Thomas F. , Investigators, The TRANSNET

Mayo Clinic

Transplant Infectious Disease | September 19, 2016 | Volume: 18 | Issue: 6 | Pages: 921-931

10.1111/tid.12613 | PMID 27643395 Get It

AbstractBackgroundInvasive candidiasis (IC) is a common cause of mortality in solid organ transplant recipients (OTRs), but knowledge of epidemiology in this population is limited.MethodThe present analysis describes data from 15 US centers that prospectively identified IC from nearly 17 000 OTRs. Analyses were undertaken to determine predictors of infection and mortality.ResultsA total of 639 cases of IC were identified. The most common species was Candida albicans (46.3%), followed by Candida glabrata (24.4%) and Candida parapsilosis (8.1%). In 68 cases >1 species was identified. The most common infection site was bloodstream (44%), followed by intra‐abdominal (14%). The most frequently affected allograft groups were liver (41.1%) and kidney (35.3%). All‐cause mortality at 90 days was 26.5% for all species and was highest for Candida tropicalis (44%) and C. parapsilosis (35.2%). Non‐white race and female gender were more commonly associated with non‐albicans species. A high rate of breakthrough IC was seen in patients receiving antifungal prophylaxis (39%). Factors associated with mortality include organ dysfunction, lung transplant, and treatment with a polyene antifungal. The only modifiable factor identified was choice of antifungal drug class based upon infecting Candida species.ConclusionThese data highlight the common and distinct features of IC in OTRs.
Preventing our Caregivers from Becoming Patients – Challenges, Successes, and Trends Faced by Hospital Risk Managers and Ergonomists
James, Tamara , Kumpar, Dee, Williamson, R. Anthony , Wolf, Laurie , Wiggermann, Neal E. , Hallbeck, M. Susan , Williamson, Robert

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | September 15, 2016 | Volume: 60 | Issue: 1 | Pages: 965-969

10.1177/1541931213601223 Get It

Healthcare workers suffer musculoskeletal disorders at rates that exceed most other industries. Despite this, many healthcare facilities do not follow best practices that are proven to reduce risk of injury. This discussion panel will explore the reasons for why the healthcare industry struggles to prevent injuries and will outline successful strategies for protecting workers. The panelists are leaders and advisors for large medical systems and their specialties include ergonomics, safe patient handling, and patient safety. The panelists relate the critical challenges faced when preventing caregiver injuries. Such challenges include underreporting of staff injuries, lack of funding or administrative support, and inability to sell the connections among caregiver safety, caregiver productivity, and patient safety. The panelists also share success stories of when they have achieved positive change and explain the strategies that were effective. Practitioners should gain new insights for implementing successful change, and researchers will be exposed to new and important research questions.
Real-time remote physiological monitoring
Ardoin, Wil-Johneen, Hoyle, W. Sloane, Bewaji, Oluwatosin, Ferris, Thomas K. , Peres, S. Camille , Kaplan, Revelee, Brady, Peter A. , Ardoin, Wil-Johneen, Bewaji, Oluwatosin, Hallbeck, M. Susan

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | September 15, 2016 | Volume: 60 | Issue: 1 | Pages: 618-622

10.1177/1541931213601141 Get It

Researchers at a large Midwest Tertiary Care Hospital have developed a remote monitoring system that supports 24-hour real-time physiological monitoring of multiple noncritical care patients from a central remote display station. The system’s potential to revolutionize the healthcare industry has encouraged future plans to expand the operation. However, all of the system’s characteristics and how those characteristics interact to affect qualities of interest such as worker efficiency, fatigue, and patient care have not been fully explored. A mixed-methods ethnographic approach was used to identify and more comprehensively understand characteristics of the remote monitoring systems currently in place. Analyses described three remote monitoring paradigms, emphasizing elements of communication that were perceived to impact patient care. These efforts are the first steps in continued analyses of remote monitoring systems and are important in the identification of key system elements intended to construct a fundamental remote monitoring model.